Development of oncology drugs

Development of advanced generic oncology drugs for targeted therapies, making cutting-edge therapies available for the widest possible range of patients.

START DATE: 2021-01-01

Target

Goals

Within the confines of this project - in collaboration with the Research Centre for Natural Sciences - Egis develops and launches advanced generic oncology drugs suitable for targeted therapies to make cutting-edge treatments available for the widest possible range of patients.

Results

Expected results

By the end of the four-year project, a pharmaceutical is expected to be on the market as well as two products ready for authorisation, fourteen new active ingredients or formulation technologies will be created.

These drug developments will significantly strengthen Egis' international competitiveness and its market position. In addition to the primary goal of product and technology developments, intellectual property (scientific publications, conference presentations, know-how, patent applications) is expected to be created as well, which will be of value to both the national and international scientific community. A further expected outcome of the project will be the expansion of Egis' cooperation with external partners (research institutes, small companies).

Description

Information on the proposed project:
● Principal of the tender: National Research, Development, and Innovation Office
● Title and code of the call for tender proposals: “Support for market-driven R&D and innovation projects” 2020-1.1.2-PIACI KFI
● Title and ID of proposed project: Development of innovative, high added-value oncology drugs for personalised therapies,”, 2020-1.1.2-PIACI-KFI-2020-00039
●Submission date of proposal: 18.09.2020
● Date of decision about funding: 01.12.2020
● Granted amount and funding intensity in total: HUF 798,000,000 (55.5%)

of which
● Consortium leader:
Egis Pharmaceuticals PLC: HUF 654,193,621 (65 or 40%)
● Consortium partner:
● The Research Centre for Natural Sciences: HUF 143,806, 379 (100%)
● Duration of the projekt:
01.01.2021 – 31.12.2024
● Total costs of the project: HUF 1,437,822,630